文献速递心力衰竭与心肌病

静脉铁剂治疗心力衰竭患者的随机试验原理与设计

Rationale and design of a randomised trial of intravenous iron in patients with heart failure.
PubMed 文献 · Heart · 2022-11-24

IRONMAN 试验为前瞻性、随机、开放标签、盲终点事件驱动研究,纳入 LVEF≤45% 且铁缺乏的 HFrEF 患者,比较静脉铁剂与标准治疗对心衰住院和心血管死亡复合终点的影响。

要点

  • 评估反复静脉铁剂对 HFrEF 合并铁缺乏患者的长期获益与安全性。
  • 主要终点为心衰总住院与心血管死亡的复合终点。
  • 感染导致的住院和死亡为安全性终点。

核心结论

  • IRONMAN 将确定重复静脉铁剂对广泛 HFrEF 合并铁缺乏患者长期治疗是否获益且安全。

研究设计与样本

  • 前瞻性、随机、开放标签、盲终点事件驱动的 IRONMAN 试验。
  • 纳入年龄≥18 岁、LVEF≤45% 且铁缺乏(铁蛋白<100 µg/L 和/或 TSAT<20%)的 HFrEF 患者。
  • 患者需当前或近期因心衰住院或血浆利钠肽浓度升高。
  • 随机接受或不接受静脉去铁麦芽糖铁,并联合指南推荐的 HFrEF 治疗。
  • 每 4 个月给药一次,若铁蛋白<100 µg/L 或铁蛋白≤400 µg/L 且 TSAT<25%。

关键数值与推荐

  • 主要终点为心衰总住院与心血管死亡的复合终点。
  • 安全性终点为感染导致的住院和死亡。
  • 铁缺乏定义:铁蛋白<100 µg/L 和/或 TSAT<20%。
  • 给药触发条件:铁蛋白<100 µg/L 或铁蛋白≤400 µg/L 且 TSAT<25%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: For patients with a reduced left ventricular ejection fraction (LVEF) heart failure with reduced ejection fraction (HFrEF) and iron deficiency, administration of intravenous iron improves symptoms, exercise capacity and may in the following 12 months, reduce hospitalisations for heart failure. The Effectiveness of Intravenous iron treatment versus standard care in patients with heart failure and iron deficiency (IRONMAN) trial evaluated whether the benefits of intravenous iron persist in the longer term and impact on morbidity and mortality. METHODS: IRONMAN is a prospective, randomised, open-label, blinded endpoint (PROBE) event-driven trial. Patients aged ≥18 years with HFrEF (LVEF ≤45%) and evidence of iron deficiency (ferritin <100 µg/L and/or TSAT <20%) were enrolled if they had either a current or recent hospitalisation for heart failure or elevated plasma concentrations of a natriuretic peptide. Participants were randomised to receive, or not to receive, intravenous ferric derisomaltose in addition to guideline-recommended therapy for HFrEF. Every 4 months, intravenous iron was administered if either ferritin was <100 µg/L or, provided ferritin was ≤400 µg/L, TSAT was <25%. The primary endpoint is a composite of total hospitalisations for heart failure and cardiovascular death. Hospitalisation and deaths due to infection are safety endpoints. RESULTS: Trial recruitment was completed across 70 UK hospital sites in October 2021. Participants were followed until the end of March 2022. We plan to report the results by November 2022. CONCLUSIONS: IRONMAN will determine whether repeated doses of intravenous ferric derisomaltose are beneficial and safe for the long-term treatment of a broad range of patients with HFrEF and iron deficiency. TRIAL REGISTRATION NUMBER: NCT02642562.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Kalra, Cleland, Petrie, et al. Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart. 2022. PMID: 35948408. doi:10.1136/heartjnl-2022-321304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。